Companies /Healthcare
Cytokinetics Inc
NASDAQ: CYTK Biotechnology
$61.62
▼ $1.17 (−1.86%) today
Markets closed · 5:50am ET

Cytokinetics (CYTK) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
50%
EPS beat rate
−7.61%
Avg. EPS surprise
Consecutive EPS beats
CYTK vs Market · 30-day return after each reportCYTKS&P 500
0%+20%+40%+0.3%+6.9%Q1 25+52.5%+2.4%Q2 25+2.2%+1.9%Q3 25−0.6%−8.5%Q4 25−9.3%+0.7%Q1 26−3.5%−1.4%Q2 26
0%+20%+40%Q1 25Q3 25Q1 26
CYTK EPS Trend · estimate vs actualEstimateActual
$-2.40$-1.60$-0.80$0.00$-1.36$-1.36Q1 25$-1.34$-1.12Q2 25$-1.63$-2.55Q3 25$-1.37$-1.50Q4 25$-1.63$-1.67Q1 26$-1.60$-1.50Q2 26
$-2.40$-1.60$-0.80$0.00Q1 25Q3 25Q1 26
CYTK Revenue Trend · estimate vs actualEstimateActual
$0$20.0M$40.0M$60.0M$2.6M$1.6MQ1 25$2.1M$66.8MQ2 25$6.4M$1.9MQ3 25$8.0M$17.8MQ4 25$9.1M$19.4MQ1 26$17.5M$28.6MQ2 26
$0$20.0M$40.0M$60.0MQ1 25Q3 25Q1 26

How Often Does Cytokinetics Beat Earnings Estimates?

Cytokinetics beat EPS estimates in 3 of its last 6 reported quarters.

CYTK quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 Includes $20.2 million non-cash interest expense related to revenue participation right purchase agreements and $1.1 million loss from change in fair value of derivative liabilities; Q2 2025 comparison included $14.6 million change in fair value of derivative liabilities and $64.4 million in non-recurring license and milestone revenues $-1.50 est. $-1.60 +6.30% $28.6M est. $17.5M +63.93%
Q1 2026 $-1.67 est. $-1.63 −2.31% $19.4M est. $9.1M +113.25%
Q4 2025 $-1.50 est. $-1.37 −9.67% $17.8M est. $8.0M +121.30%
Q3 2025 $-2.55 est. $-1.63 −56.33% $1.9M est. $6.4M −69.88%
Q2 2025 $-1.12 est. $-1.34 +16.12% $66.8M est. $2.1M +3,131.07%
Q1 2025 $-1.36 est. $-1.36 +0.23% $1.6M est. $2.6M −39.51%

Figures from SEC filings and company reports. Not investment advice.